Benzinga | Oct 12, 2020 08:08AM EDT

Ardelyx Highlights Presentation Of Tenapanor Data At ASN's Kidney Week 2020 Oct. 22-25

FREMONT, Calif., Oct. 12, 2020 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that five abstracts on tenapanor have been accepted for presentation at Kidney Week 2020, the American Society of Nephrology's (ASN) Annual Meeting, to be held October 22-25, 2020. Tenapanor, which was discovered and developed by Ardelyx, is a first-in-class therapy under review for potential marketing approval by the U.S. Food and Drug Administration (FDA) for the control of serum phosphorus in adult patients with CKD on dialysis.

Three poster presentations highlight data from several Phase 3 trials in the U.S., including the BLOCK, AMPLIFY and PHREEDOM studies. Additionally, the company's partner for tenapanor in Japan, Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151), will present results from two Phase 2 studies evaluating the efficacy and safety of tenapanor in Japanese patients on hemodialysis.

Information regarding ASN's Kidney Week, including copies of presentation abstracts, can be found at https://www.asn-online.org/education/kidneyweek.

Ardelyx Poster Presentations:

Long-term Safety and Efficacy of Tenapanor for the Control ofTitle: Serum Phosphorus in Patients with CKD on Dialysis

Abstract 3450189Number:

ePoster Number: PO0384

Date/Time: Thursday, October 22, 10:00 a.m. EDT

Efficacy of Tenapanor for the Control of Serum Phosphorus in

Title: Patients with CKD on Dialysis: Novel Mechanism of Action Allows

for Both Monotherapy and Dual Mechanism Approach

Abstract 3450673Number:

ePoster Number: PO0374

Date/Time: Thursday, October 22, 10:00 a.m. EDT





Tolerability of Tenapanor, an Investigational, First-in-Class, Non-Title: Binder Therapy for the Control of Serum Phosphorus in Patients

with CKD on Dialysis

Abstract 3450921Number:

ePoster Number: PO0376

Date/Time: Thursday, October 22, 10:00 a.m. EDT



Kyowa Kirin Poster Presentations:

Dose-Response Efficacy and Tolerability of Tenapanor on

Title: Hyperphosphatemia in Japanese Hemodialysis Patients: Results of a

Randomized Phase 2 Study

Abstract 3435825Number:

ePoster Number: PO0382

Date/Time: Thursday, October 22, 10:00 a.m. EDT



Efficacy and Safety of Add-on Tenapanor to Phosphate Binders forTitle: Refractory Hyperphosphatemia in Japanese Patients on

Hemodialysis: A Phase 2, Double-Blind Study

Abstract 3439266Number:

ePoster Number: PO0375

Date/Time: Thursday, October 22, 10:00 a.m. EDT